Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEECH: AZD5363 plus paclitaxel in advanced or metastatic breast cancer
NL-OMON37581Phase 1Withdrawn
- Sponsor
- AstraZeneca
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of capivasertib and paclitaxel in breast cancer, sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD5363 schedules with weekly paclitaxel and Relative anti-tumor activity at 12 weeks. Planned start May 2012; status: withdrawn.
02
Drugs
capivasertibpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON37581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37581.